+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Retroviral Drugs Market by Product Type, Route Of Administration, Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast to 2030- Product Image
Anti-Retroviral Drugs Market by Product Type, Route Of Administration, Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast to 2030- Product Image
Sale

Anti-Retroviral Drugs Market by Product Type, Route Of Administration, Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015172
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Retroviral Drugs Market grew from USD 29.05 billion in 2024 to USD 30.44 billion in 2025. It is expected to continue growing at a CAGR of 4.63%, reaching USD 38.13 billion by 2030.

Navigating the Anti-Retroviral Frontier with Clarity and Depth

The anti-retroviral drugs sector has entered an era defined by rapid innovation and shifting global health priorities. As healthcare systems worldwide strive to optimize treatment outcomes for individuals living with HIV, the market landscape continues to evolve under the influence of new molecular breakthroughs, policy reforms, and changing patient demographics. This executive summary synthesizes the critical developments shaping the anti-retroviral arena, offering decision-makers a concise yet comprehensive overview of emerging trends, regulatory impacts, and competitive dynamics.

By highlighting the transformative shifts in therapeutic approaches, examining the ripple effects of United States tariff changes taking effect in 2025, and elucidating nuanced segmentation and regional variations, this summary delivers a strategic foundation. Stakeholders will find clarity in the segmentation insights that reveal how product types, routes of administration, formulations, end-user channels, distribution pathways, therapy lines, and patient groups converge to influence market trajectories. Ultimately, this introduction lays the groundwork for informed strategy formulation and targeted investments.

Breakthrough Science and Policy Driving New Treatment Paradigms

Recent years have witnessed a fundamental reshaping of the anti-retroviral drugs landscape, driven by a confluence of scientific breakthroughs and evolving patient care paradigms. Novel integrase strand transfer inhibitors have become cornerstone agents in first-line regimens, challenging the long-standing dominance of reverse transcriptase and protease inhibitors. Meanwhile, the expiration of key patents has intensified competition, enabling generic manufacturers to enter markets with cost-effective alternatives that expand access in resource-constrained settings.

Digital health platforms now underpin patient adherence programs, providing real-time monitoring and behavior insights that augment clinical trial data. Combination therapies are increasingly personalized based on genetic profiling and co-morbidities, ushering in an era of precision antiretroviral therapy. Policy frameworks in major markets are adapting to these innovations, revising reimbursement guidelines to foster value-based care. As a result, the ecosystem is rapidly transitioning from a one-size-fits-all model toward targeted interventions that optimize outcomes while controlling costs.

Navigating Tariff Shifts to Safeguard Supply and Affordability

With the United States implementing revised tariff schedules in 2025, the anti-retroviral market faces fresh cost pressures and supply chain complexities. Tariff adjustments on active pharmaceutical ingredients imported from key manufacturing hubs are anticipated to elevate pricing for branded and generic medications alike. Companies must anticipate the knock-on effects on procurement budgets, as higher import duties can cascade through distribution networks and healthcare contracts.

Manufacturers are exploring alternative sourcing strategies, including closer-to-market production partnerships and regional manufacturing alliances, to offset increased duties. Meanwhile, philanthropic and government procurement programs are negotiating tiered pricing agreements to maintain treatment affordability in low-income regions. The confluence of tariff-driven cost inflations and strategic mitigation measures underscores the importance of agile supply chain planning. Organizations that proactively adapt sourcing configurations and collaborate with policy stakeholders will be best positioned to sustain market share and preserve patient access.

Deep Dive into Market Segmentation Dynamics

Insight into market segmentation reveals the intricate mosaic of factors that govern anti-retroviral adoption and growth. When analyzing product types-spanning CCR5 antagonists, fusion inhibitors, integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors-each class exhibits distinct efficacy profiles, resistance patterns, and lifecycle dynamics. Route of administration further differentiates market penetration, with oral therapies retaining widespread use while parenteral options gain traction in advanced treatment protocols.

Formulation preferences underscore the importance of patient convenience and dosing flexibility. Injectable formats, whether administered intravenously or subcutaneously, cater to supervised care settings, whereas oral liquids-available in solution or suspension-address pediatric and dysphagia populations. Oral solids, whether capsules or tablets, remain the backbone of outpatient regimens. End-user channels underscore diversity in care delivery, as home care models, hospital systems, and specialty clinics each demand tailored distribution approaches. Distribution channels themselves-from hospital pharmacies to online and retail pharmacies-shape prescribing behavior and patient access. Within therapy lines, first-line regimens command volume, while second-line and salvage therapies address resistance management. Finally, patient group dynamics-adult versus pediatric-underscore the need for age-appropriate formulations and adherence support.

Regional Variations Shaping Global Anti-Retroviral Trends

Regional insights highlight the nuanced forces at play across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust healthcare infrastructure and strong reimbursement ecosystems drive the uptake of advanced combination therapies, supported by proactive public health initiatives. Europe, Middle East & Africa presents a heterogeneous mix: western European markets emphasize high-value patented therapies, while emerging economies focus on generic access facilitated by international aid programs and local manufacturing efforts.

Across Asia-Pacific, rapid urbanization and expanding healthcare coverage are fueling demand for cost-effective regimens, with several nations catalyzing domestic production to reduce import dependencies. Regional regulatory harmonization efforts aim to streamline approvals, encouraging cross-border collaboration and bolstering supply resilience. As procurement models evolve-from centralized tenders to decentralized purchasing-the interplay of local policies and private sector engagement continues to redefine market trajectories in each geographical cluster.

Competitive Landscape Spotlight on Leading Industry Players

Leading players in the anti-retroviral space are deploying differentiated strategies to secure competitive advantage. Established pharmaceutical companies are accelerating pipeline innovation through strategic alliances and in-licensing deals that expand their portfolios into next-generation integrase inhibitors and novel long-acting formulations. Simultaneously, generic manufacturers are leveraging economies of scale and specialized manufacturing capabilities to undercut pricing, particularly in emerging markets where volume commitments drive procurement decisions.

Partnerships between innovators and generics are increasingly common, facilitating technology transfers that shorten time-to-market for new formulations. Biotech entrants are focusing on niche indications and bespoke therapies, seeking to carve out segments within heavily populated therapeutic categories. Together, these dynamics create a competitive tapestry in which agility, scale, and collaborative reach determine market positioning.

Strategic Pillars for Future Growth and Resilience

Industry leaders should prioritize several strategic imperatives to stay ahead. First, diversifying supply chains through regional manufacturing partnerships will mitigate tariff-driven cost inflations and enhance distribution resilience. Second, investing in next-generation therapies-such as long-acting injectables and novel mechanism agents-will sustain differentiation in crowded therapeutic classes. Third, strengthening patient support programs through digital adherence tools and telemedicine platforms will improve outcomes and foster loyalty.

Moreover, forging public-private collaborations can unlock value-based procurement models and ensure treatment affordability in resource-limited settings. Pursuing adaptive pricing strategies that align with regional economic realities will maintain market access while preserving margins. Finally, integrating real-world evidence generation into clinical development and post-launch activities will substantiate value propositions and guide iterative improvements.

Rigorous Methodology Underpinning Robust Market Insights

This analysis is underpinned by a rigorous methodology combining comprehensive secondary research with targeted primary engagements. Publicly available regulatory filings, peer-reviewed literature, and industry white papers were systematically reviewed to establish a foundational data set. Primary interviews with key opinion leaders, procurement specialists, and regional market experts provided qualitative depth and validated emerging trends.

Data triangulation techniques were employed to reconcile discrepancies across sources, ensuring consistency and reliability. Segmentation assumptions were defined through iterative consultations with clinical and commercial stakeholders, while geographic analyses considered macroeconomic indicators and health policy developments. All research activities adhered to ethical standards, with confidentiality and data integrity maintained throughout.

Concluding Synthesis of Market Imperatives

In conclusion, the anti-retroviral drugs market stands at a crossroads defined by innovation, policy evolution, and shifting access dynamics. Transformative science is driving the adoption of precision therapies, while regulatory environments and tariff shifts mandate agile strategic responses. Nuanced segmentation and regional analysis reveal a landscape of divergent growth levers, and companies that blend R&D excellence with supply chain adaptability will secure leadership.

As the market continues to mature, collaboration across public and private sectors will be essential to reconcile cost pressures with patient-centric objectives. By aligning strategic investments with emerging clinical paradigms and leveraging robust market intelligence, stakeholders can navigate complexity and capitalize on the promising horizon of anti-retroviral treatment advancement.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Ccr5 Antagonists
    • Fusion Inhibitors
    • Integrase Strand Transfer Inhibitors
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Nucleoside Reverse Transcriptase Inhibitors
    • Protease Inhibitors
  • Route Of Administration
    • Oral
    • Parenteral
  • Formulation
    • Injectable
      • Intravenous
      • Subcutaneous
    • Oral Liquid
      • Solution
      • Suspension
    • Oral Solid
      • Capsule
      • Tablet
  • End User
    • Home Care
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Therapy Line
    • First Line
    • Salvage Therapy
    • Second Line
  • Patient Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Gilead Sciences, Inc.
  • ViiV Healthcare ULC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Lupin Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Retroviral Drugs Market, by Product Type
8.1. Introduction
8.2. Ccr5 Antagonists
8.3. Fusion Inhibitors
8.4. Integrase Strand Transfer Inhibitors
8.5. Non-Nucleoside Reverse Transcriptase Inhibitors
8.6. Nucleoside Reverse Transcriptase Inhibitors
8.7. Protease Inhibitors
9. Anti-Retroviral Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Anti-Retroviral Drugs Market, by Formulation
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral Liquid
10.3.1. Solution
10.3.2. Suspension
10.4. Oral Solid
10.4.1. Capsule
10.4.2. Tablet
11. Anti-Retroviral Drugs Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Specialty Clinics
12. Anti-Retroviral Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Anti-Retroviral Drugs Market, by Therapy Line
13.1. Introduction
13.2. First Line
13.3. Salvage Therapy
13.4. Second Line
14. Anti-Retroviral Drugs Market, by Patient Group
14.1. Introduction
14.2. Adult
14.3. Pediatric
15. Americas Anti-Retroviral Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Anti-Retroviral Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Anti-Retroviral Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Gilead Sciences, Inc.
18.3.2. ViiV Healthcare ULC
18.3.3. Johnson & Johnson
18.3.4. Merck & Co., Inc.
18.3.5. Bristol-Myers Squibb Company
18.3.6. Teva Pharmaceutical Industries Ltd.
18.3.7. Viatris Inc.
18.3.8. Cipla Limited
18.3.9. Aurobindo Pharma Limited
18.3.10. Lupin Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ANTI-RETROVIRAL DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-RETROVIRAL DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-RETROVIRAL DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 127. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 132. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 133. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 136. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 137. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 142. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 157. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 162. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 172. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 173. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 176. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 207. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 212. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 213. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 216. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 232. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 233. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 236. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 237. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 242. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 267. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 270. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 272. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 273. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 276. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 277. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 281. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 282. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 283. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 286. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 297. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 300. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 301. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 302. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 303. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 307. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 310. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 311. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 312. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 316. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2030 (USD MILLION)
TABLE 327. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 330. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC ANTI-RETROVIRAL DRUG

Companies Mentioned

The companies profiled in this Anti-Retroviral Drugs market report include:
  • Gilead Sciences, Inc.
  • ViiV Healthcare ULC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Lupin Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 30.44 Billion
Forecasted Market Value ( USD ) by 2030 $ 38.13 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anti-Retroviral Drugs - Global Strategic Business Report - Product Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Anti-Retroviral Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Anti-Retroviral Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 95 Pages
  • Global
From
2025 Global Forecast for Anti-Retroviral Drugs (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Anti-Retroviral Drugs (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
HIV Integrase Inhibitors - Pipeline Insight, 2025 - Product Image

HIV Integrase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode of Administration, Patient Type, Distribution Channel - Global Forecast to 2030 - Product Image

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode of Administration, Patient Type, Distribution Channel - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From

About the Antiretroviral Market

The antiretroviral market is a subset of the HIV/AIDS drugs market, which is focused on the development and sale of drugs that can be used to treat HIV/AIDS. Antiretroviral drugs are used to reduce the amount of HIV in the body, and can be used to prevent the transmission of HIV from one person to another. These drugs are typically used in combination with other treatments, such as counseling and lifestyle changes, to help people living with HIV/AIDS manage their condition. The antiretroviral market is highly competitive, with many companies developing and selling drugs to treat HIV/AIDS. Some of the major players in the market include Gilead Sciences, Merck, Bristol-Myers Squibb, GlaxoSmithKline, and ViiV Healthcare. Other companies, such as AbbVie, Janssen, and Mylan, also have a presence in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.